慢性乙肝患者停用拉米夫定后出现肝功能衰竭的危险因素分析 - 长沙163医院肝病治疗中心 著性差异(Z=3?49，P＜0.01)。服用拉米夫定前诊断为CHB轻度42例、中度15例、重度4例，乙型肝炎代偿性肝硬化(compensatedlivercirrhosis，CLC)2例、失代偿性肝硬化(decompensatedlivercirrhosis，DLC)8例。全部排除
基于4个网页-相关网页
...拉米夫定前诊断为CHB轻度42例、中度15例、重度4例，乙型肝炎代偿性肝硬化(compensatedlivercirrhosis，CLC)2例、失代偿性肝硬化(decompensatedlivercirrhosis，DLC)8例。
基于1个网页-相关网页
结果代偿性肝硬化组服用软肝片后效果明显，失代偿性肝硬化组无明显疗效。
Results the curative effect on the compensatory cirrhosis treated group was significantly better than the decompensated cirrhosis group.
目的研究结肠灌注透析对失代偿性肝硬化顽固性腹水及内毒素血症、高氨血症、低钠血症的治疗效果。
Objective to study the curative effect of the colon perfusion dialysis for the decompensated hepatocirrhosis with intractable ascites, endotoxemia, hyperammonemia and hyponatremia.
结论结肠灌注透析治疗对失代偿性肝硬化顽固性腹水及内毒素血症、高氨血症、低钠血症均有较好的近期疗效。
Conclusion Colon perfusion dialysis therapy had good short-term effect on the decompensated hepatocirrhosis with intractable ascites, endotoxemia, hyperammonemia and hyponatremia.
应用推荐